Fluoroquinolone disposition: Identification of the contribution of renal secretory and reabsorptive drug transporters

Aditi Mulgaonkar, Jurgen Venitz, Douglas H. Sweet

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Fluoroquinolones (FQs) exist as charged molecules in blood and urine making their absorption, distribution, and elimination likely to be influenced by active transport mechanisms. Greater understanding of in vivo FQ clearance mechanisms should help improve the predictability of drugdrug interactions, enhance the clinical safety and efficacy, and aid future novel drug design strategies. Areas covered: The authors present an overview of FQ development and associated drugdrug interactions, followed by systematic quantitative review of the physicochemical and in vivo pharmacokinetic properties for 15 representative FQs using historical clinical literature. These results were correlated with in vitro studies implicating drug transporters in FQ clearance to link clinical and in vitro evidence supporting the contribution of drug transport mechanisms to FQ disposition. Specific transporters likely to handle FQs in human renal proximal tubule cells are also identified. Expert opinion: Renal handling, that is, tubular secretion and reabsorption, appears to be the main determinant of FQ plasma half-life, clinical duration of action, and drugdrug interactions. Due to their zwitterionic nature, FQs are likely to interact with organic anion and cation transporters within the solute carrier (SLC) superfamily, including OAT1, OAT3, OCT2, OCTN1, OCTN2, MATE1, and MATE2. The ATP-binding cassette (ABC) transporters MDR1, MRP2, MRP4, and BCRP also may interact with FQs.

Original languageEnglish (US)
Pages (from-to)553-569
Number of pages17
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume8
Issue number5
DOIs
StatePublished - May 1 2012
Externally publishedYes

Fingerprint

Fluoroquinolones
Kidney
Pharmaceutical Preparations
Organic Anion Transporters
Proximal Kidney Tubule
Pharmacokinetics
ATP-Binding Cassette Transporters
Active Biological Transport
Drug Design
Expert Testimony
Anions
Half-Life
Cations
Blood
Urine
Plasmas
Safety
Molecules

Keywords

  • ABC transporters
  • drug disposition
  • fluoroquinolones
  • kidney
  • organic anion transporters
  • organic cation transporters
  • pharmacokinetics
  • SLC transporters

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Fluoroquinolone disposition : Identification of the contribution of renal secretory and reabsorptive drug transporters. / Mulgaonkar, Aditi; Venitz, Jurgen; Sweet, Douglas H.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 8, No. 5, 01.05.2012, p. 553-569.

Research output: Contribution to journalReview article

@article{7332978b31644471aee3cc5b8f3ef5d3,
title = "Fluoroquinolone disposition: Identification of the contribution of renal secretory and reabsorptive drug transporters",
abstract = "Fluoroquinolones (FQs) exist as charged molecules in blood and urine making their absorption, distribution, and elimination likely to be influenced by active transport mechanisms. Greater understanding of in vivo FQ clearance mechanisms should help improve the predictability of drugdrug interactions, enhance the clinical safety and efficacy, and aid future novel drug design strategies. Areas covered: The authors present an overview of FQ development and associated drugdrug interactions, followed by systematic quantitative review of the physicochemical and in vivo pharmacokinetic properties for 15 representative FQs using historical clinical literature. These results were correlated with in vitro studies implicating drug transporters in FQ clearance to link clinical and in vitro evidence supporting the contribution of drug transport mechanisms to FQ disposition. Specific transporters likely to handle FQs in human renal proximal tubule cells are also identified. Expert opinion: Renal handling, that is, tubular secretion and reabsorption, appears to be the main determinant of FQ plasma half-life, clinical duration of action, and drugdrug interactions. Due to their zwitterionic nature, FQs are likely to interact with organic anion and cation transporters within the solute carrier (SLC) superfamily, including OAT1, OAT3, OCT2, OCTN1, OCTN2, MATE1, and MATE2. The ATP-binding cassette (ABC) transporters MDR1, MRP2, MRP4, and BCRP also may interact with FQs.",
keywords = "ABC transporters, drug disposition, fluoroquinolones, kidney, organic anion transporters, organic cation transporters, pharmacokinetics, SLC transporters",
author = "Aditi Mulgaonkar and Jurgen Venitz and Sweet, {Douglas H.}",
year = "2012",
month = "5",
day = "1",
doi = "10.1517/17425255.2012.674512",
language = "English (US)",
volume = "8",
pages = "553--569",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Fluoroquinolone disposition

T2 - Identification of the contribution of renal secretory and reabsorptive drug transporters

AU - Mulgaonkar, Aditi

AU - Venitz, Jurgen

AU - Sweet, Douglas H.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Fluoroquinolones (FQs) exist as charged molecules in blood and urine making their absorption, distribution, and elimination likely to be influenced by active transport mechanisms. Greater understanding of in vivo FQ clearance mechanisms should help improve the predictability of drugdrug interactions, enhance the clinical safety and efficacy, and aid future novel drug design strategies. Areas covered: The authors present an overview of FQ development and associated drugdrug interactions, followed by systematic quantitative review of the physicochemical and in vivo pharmacokinetic properties for 15 representative FQs using historical clinical literature. These results were correlated with in vitro studies implicating drug transporters in FQ clearance to link clinical and in vitro evidence supporting the contribution of drug transport mechanisms to FQ disposition. Specific transporters likely to handle FQs in human renal proximal tubule cells are also identified. Expert opinion: Renal handling, that is, tubular secretion and reabsorption, appears to be the main determinant of FQ plasma half-life, clinical duration of action, and drugdrug interactions. Due to their zwitterionic nature, FQs are likely to interact with organic anion and cation transporters within the solute carrier (SLC) superfamily, including OAT1, OAT3, OCT2, OCTN1, OCTN2, MATE1, and MATE2. The ATP-binding cassette (ABC) transporters MDR1, MRP2, MRP4, and BCRP also may interact with FQs.

AB - Fluoroquinolones (FQs) exist as charged molecules in blood and urine making their absorption, distribution, and elimination likely to be influenced by active transport mechanisms. Greater understanding of in vivo FQ clearance mechanisms should help improve the predictability of drugdrug interactions, enhance the clinical safety and efficacy, and aid future novel drug design strategies. Areas covered: The authors present an overview of FQ development and associated drugdrug interactions, followed by systematic quantitative review of the physicochemical and in vivo pharmacokinetic properties for 15 representative FQs using historical clinical literature. These results were correlated with in vitro studies implicating drug transporters in FQ clearance to link clinical and in vitro evidence supporting the contribution of drug transport mechanisms to FQ disposition. Specific transporters likely to handle FQs in human renal proximal tubule cells are also identified. Expert opinion: Renal handling, that is, tubular secretion and reabsorption, appears to be the main determinant of FQ plasma half-life, clinical duration of action, and drugdrug interactions. Due to their zwitterionic nature, FQs are likely to interact with organic anion and cation transporters within the solute carrier (SLC) superfamily, including OAT1, OAT3, OCT2, OCTN1, OCTN2, MATE1, and MATE2. The ATP-binding cassette (ABC) transporters MDR1, MRP2, MRP4, and BCRP also may interact with FQs.

KW - ABC transporters

KW - drug disposition

KW - fluoroquinolones

KW - kidney

KW - organic anion transporters

KW - organic cation transporters

KW - pharmacokinetics

KW - SLC transporters

UR - http://www.scopus.com/inward/record.url?scp=84859981569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859981569&partnerID=8YFLogxK

U2 - 10.1517/17425255.2012.674512

DO - 10.1517/17425255.2012.674512

M3 - Review article

C2 - 22435536

AN - SCOPUS:84859981569

VL - 8

SP - 553

EP - 569

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 5

ER -